Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Cash from Financing Activities (2018 - 2022)

Historic Cash from Financing Activities for Iterum Therapeutics (ITRM) over the last 5 years, with Q4 2022 value amounting to $433000.0.

  • Iterum Therapeutics' Cash from Financing Activities rose 12658.07% to $433000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.8 million, marking a year-over-year decrease of 10218.7%. This contributed to the annual value of $26.7 million for FY2024, which is 248133.46% up from last year.
  • As of Q4 2022, Iterum Therapeutics' Cash from Financing Activities stood at $433000.0, which was up 12658.07% from -$2.3 million recorded in Q1 2022.
  • Over the past 5 years, Iterum Therapeutics' Cash from Financing Activities peaked at $88.7 million during Q2 2018, and registered a low of -$2.3 million during Q1 2022.
  • For the 5-year period, Iterum Therapeutics' Cash from Financing Activities averaged around $15.9 million, with its median value being $767000.0 (2020).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 9351428.57% in 2020, then tumbled by 31303.78% in 2021.
  • Iterum Therapeutics' Cash from Financing Activities (Quarter) stood at $1.4 million in 2018, then plummeted by 175.53% to -$1.0 million in 2019, then skyrocketed by 1562.96% to $15.1 million in 2020, then crashed by 110.77% to -$1.6 million in 2021, then skyrocketed by 126.58% to $433000.0 in 2022.
  • Its Cash from Financing Activities stands at $433000.0 for Q4 2022, versus -$2.3 million for Q1 2022 and -$1.6 million for Q4 2021.